Physician profile
Jeffrey Dickman
NPI 1225598675
$7,323.04
in general payments reported to CMS, 2019-2025
26 companies · $3,405 in 2025
The $3,405 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $518 · 2023: $815 · 2024: $2,466 · 2025: $3,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,669 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,669.33 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,678.12 | 2022-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $630.26 | 2021-2025 | |
| Janssen Biotech, INC. | $614.69 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $568.99 | 2022-2025 | Blu-U, Odomzo, Ilumya |
| Ucb, INC. | $445.71 | 2024-2025 | Bimzelx |
| Amgen INC. | $442.98 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $398.99 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $356.66 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $354.00 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $348.02 | 2024-2025 | Adbry, Anzupgo |
| Organon LLC | $261.45 | 2024-2025 | Vtama, Hadlima |
| Dermavant Sciences, INC. | $258.98 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $219.20 | 2024-2025 | Nemluvio, Aklief |
| Incyte Corporation | $193.78 | 2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $135.03 | 2023-2025 | Sotyktu |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $98.63 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $78.79 | 2023-2025 | Zoryve |
| Biowound Solutions, INC. | $51.25 | 2025 | Bio-Connekt |
| Genentech USA, INC. | $41.45 | 2025 | Xolair |
| Botanix Sb INC | $29.87 | 2025 | Sofdra |
| Mimedx Group, INC. | $28.52 | 2025 | |
| Kyowa Kirin, INC. | $26.42 | 2025 | |
| Fidia Pharma USA INC. | $16.46 | 2024 | |
| Paratek Pharmaceuticals, INC. | $16.07 | 2023 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $15.54 | 2024 | Simlandi |
| Mayne Pharma Commercial LLC | $13.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Dickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.